Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Phase 2
372
about 9.8 years
18+
8 sites in CA, IL, MT +4
About this study
This trial is testing a treatment with patritumab deruxtecan, pembrolizumab, and other anticancer agents in people with high-risk early-stage triple-negative or hormone receptor-low positive/HER-2 negative breast cancer. The goal is to learn about the safety of these treatments and if people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Patritumab deruxtecan
- 2.Receive Pembrolizumab
- 3.Take Capecitabine
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
capecitabine, carboplatin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), Antineoplastic Agent [TC] (Topoisomerase 2 Inhibitors), Antineoplastic Agent [TC] (Immunologic Adjuvants), olaparib, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
oral (Oral Tablet), infusion, oral, injection, intravenous
Primary: Part 1: Number of Participants Experiencing an Adverse Event (AE), Part 1: Number of Participants who Discontinued Study Treatment Due to an AE, Part 2: Number of Participants Experiencing an AE, Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Secondary: Part 2: Event-Free Survival (EFS), Part 2: Overall Survival (OS)
Oncology